In the phase II GERCOR NIPICOL study, which evaluated 1 year of treatment with nivolumab plus ipilimumab in patients with chemotherapy-resistant metastatic colorectal cancer whose tumors were microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR), what percentage of patients had received at least three prior lines of chemotherapy?
